Our website uses cookies to make navigation as functional as possible. Our cookies do not enable us to identify you in any way. Should you wish to receive more information, or deny your consent to all or some of the cookies, please click here to disable them. By continuing to browse this site , you will be accepting our cookies.

News

Promising results from the  preclinical study conducted by Menarini Ricerche on  MEN1611 , a potent and selective orally available phosphatidylinosi...
The Board of Directors has appointed Mrs.  Elcin Barker Ergun   as CEO of Menarini Group.
Menarini Ricerche today announced the publication of the results of a non-clinical study describing the characterization of the anti-CD205 Antibody-D...
Third year of ‘Get Breathless for COPD’ cycle event raise over €11k for charity Cycling along Dublin’s scenic coast, participants of the third ‘Get ...
READ ALL NEWS »
ESMO Annual Meeting 2019: Menarini Ricerche presents the preclinical characterization of MEN1611, a novel PI3K inhibitor in development for the treatm

ESMO Annual Meeting 2019: Menarini Ricerche presents the preclinical characterization of MEN1611, a novel PI3K inhibitor in development for the treatm

Promising results from the  preclinical study conducted by Menarini Ricerche on  MEN1611 , a potent and selective orally available phosphatidylinositol 3-kinase (PI3K) inhibitor currently in development  for the treatment of breast cancer.

Quality first


Quality: point of departure and arrival for our drugs.

READ MORE »

Menarini in the world

The Menarini Group has companies located almost all over the world.

READ MORE »

Innovation & Research

Constant commitment to new drug research.

READ MORE »

Our values

 

10 core values have influenced the progress of our group.

READ MORE »